Overview
Dung Le, M.D. is a professor of oncology at the Johns Hopkins University School of Medicine and member of the Johns Hopkins Kimmel Cancer Center. Her research interests include novel approaches to patients with gastrointestinal malignancies. She has served as the principal investigator (PI) on many clinical trials focused on testing immunotherapy in patients with gastrointestinal malignancies and she has also served as the national PI on several studies including: anti-programmed death-1 (PD-1) in tumors with mismatch repair deficiency; a clinical trial in advanced pancreatic cancer patients evaluating the safety, tolerability and immune response to CRS-207, a listeria vaccine platform which has been modified to express the tumor antigen mesothelin; a multi-center, phase 2 study testing CRS-207 as a boost to allogenic pancreatic tumor cells transfected with GM-CSF gene (GVAX) for treatment of advanced pancreatic adenocarcinoma (PDA); a trial testing GVAX/ipilimumab in the maintenance setting for metastatic pancreatic cancer; and GVAX/CRS-207 +/- nivolumab in metastatic pancreatic cancer. These studies incorporate extensive laboratory correlates and have involved collaborations with clinicians and bench scientists with expertise in the fields of immunotherapy and cancer genomics.
Dr. Le is rated as an Advanced provider by MediFind in the treatment of Ampullary Cancer. Her top areas of expertise are Pancreatic Cancer, Colorectal Cancer, Gastroesophageal Junction Cancer, and Familial Pancreatic Cancer.
Her clinical research consists of co-authoring 6 peer reviewed articles. MediFind looks at clinical research from the past 15 years.
Insurance
Accepted insurance can change. Please verify directly with the provider.
Accepted insurance plans:
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- POS
- PPO
- HMO
- POS
- PPO
- EPO
- HMO
- PPO
- INSURANCE PLAN
- MEDICARE PDP
- PPO
- HMO
- POS
- PPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- OTHER COMMERCIAL
- OTHER MEDICARE
- OTHER MEDICARE PART D
- PPO
- HMO
- INDEMNITY
- POS
- PPO
- HMO
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE-MEDICAID PLAN
- OTHER MANAGED MEDICAID
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- OTHER MEDICARE
- OTHER MEDICARE PART D
Locations
201 North Broadway Street, Viragh BLDG 5th FL, Viragh BLDG 5th FL, Baltimore, MD 21287
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Skip Viragh Outpatient Cancer Center
Dr. Daniel Laheru is a cancer specialist in Baltimore, caring for patients with pancreatic cancer, colorectal cancer and neuroendocrine cancers. Dr. Laheru serves as co-director of the Skip Viragh Center for Pancreas Cancer Clinical Research and Patient Care at Johns Hopkins Medicine. Dr. Laheru received his undergraduate degree in chemistry from The University of Utah. He earned his M.D. at Baylor College of Medicine. He completed his residency at The University of Utah Hospital and Clinics and performed a fellowship in medical oncology at The Johns Hopkins University School of Medicine and The Johns Hopkins Oncology Center. Dr. Laheru joined the Johns Hopkins faculty in 2001. Dr. Laheru's research interests include pancreatic cancer and chemotherapy resistance in pancreatic cancer. With Elizabeth Jaffee, M.D., he developed a vaccine that supercharges the immune system and causes immune cells, which tend to be tolerant of cancer, to seek out and kill pancreatic cancer cells throughout the body. He has given numerous invited talks on pancreatic cancer and other cancers both nationally and internationally. He has authored over 200 papers focused on pancreatic cancer. Dr. Laheru serves as associate editor of Annals of Pancreatic Cancer. He has been recognized by the American Society of Clinical Oncology with the Young Investigator Award, by the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins as an Isaac and Catharine Hecht Scholar and has been elected to the Miller-Coulson Academy of Clinical Excellence. He is a member of the American College of Physicians, the American Society of Clinical Oncology and the American Association for Cancer Research. Dr. Laheru is rated as an Elite provider by MediFind in the treatment of Ampullary Cancer. His top areas of expertise are Pancreatic Cancer, Familial Pancreatic Cancer, Neuroendocrine Tumor, Pancreaticoduodenectomy, and Pancreatectomy.
Inova Health Care Services
Timothy Cannon is an Oncologist and a Hematologist in Falls Church, Virginia. Dr. Cannon is rated as a Distinguished provider by MediFind in the treatment of Ampullary Cancer. His top areas of expertise are Colorectal Cancer, Pancreatic Cancer, Familial Pancreatic Cancer, and Cholangiocarcinoma (Bile Duct Cancer). Dr. Cannon is currently accepting new patients.
Sibley Memorial Hospital
Dr. Michael Pishvaian is the director of Gastrointestinal, Developmental Therapeutics and Clinical Research Programs for the Johns Hopkins Kimmel Cancer Center in the Greater Washington Area and an associate professor at the School of Medicine. Dr. Pishvaian is a fellowship-trained gastrointestinal oncologist specializing in pancreatic and refractory colorectal cancers. He is committed to precision medicine and provides his patients with the most appropriate and advanced level of care. He conducts all phases of clinical trials for all GI cancers and enrolls qualifying patients. Click here to learn more about oncology clinical trials the Greater Washington Area. Dr. Pishvaian is rated as an Elite provider by MediFind in the treatment of Ampullary Cancer. His top areas of expertise are Pancreatic Cancer, Colorectal Cancer, Familial Pancreatic Cancer, Pancreaticoduodenectomy, and Pancreatectomy.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Elite
- Pancreatic CancerDr. Le isElite. Learn about Pancreatic Cancer.
- Distinguished
- Colorectal CancerDr. Le isDistinguished. Learn about Colorectal Cancer.
- Familial Colorectal CancerDr. Le isDistinguished. Learn about Familial Colorectal Cancer.
- Familial Pancreatic CancerDr. Le isDistinguished. Learn about Familial Pancreatic Cancer.
- Gastroesophageal Junction CancerDr. Le isDistinguished. Learn about Gastroesophageal Junction Cancer.
- Neuroendocrine TumorDr. Le isDistinguished. Learn about Neuroendocrine Tumor.
- Advanced
- Ampullary CancerDr. Le isAdvanced. Learn about Ampullary Cancer.
- Lynch SyndromeDr. Le isAdvanced. Learn about Lynch Syndrome.
- PancreatoblastomaDr. Le isAdvanced. Learn about Pancreatoblastoma.
- Experienced
- Anal CancerDr. Le isExperienced. Learn about Anal Cancer.
- Bone TumorDr. Le isExperienced. Learn about Bone Tumor.
- Cholangiocarcinoma (Bile Duct Cancer)
- Endometrial CancerDr. Le isExperienced. Learn about Endometrial Cancer.
- Gallbladder AdenocarcinomaDr. Le isExperienced. Learn about Gallbladder Adenocarcinoma.
- Gallbladder CancerDr. Le isExperienced. Learn about Gallbladder Cancer.